Roche today gave a presentation debuting its first continuous glucose monitor (CGM) offering that utilizes predictive AI. The company unveiled its Accu-Chek SmartGuide in an event at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy. It remains an investigational device not yet authorized for sale. Julien Boisdron, Roche Diabetes Care’s chief medical […]
Diabetes
Real-world data backs Abbott FreeStyle Libre CGM in tandem with GLP-1s
Abbott (NYSE:ABT) today announced data from two real-world studies highlighting the success of its CGM when used with GLP-1 drugs. Data showed that people with type 2 diabetes using GLP-1s with FreeStyle Libre had a greater improvement in HbA1c compared to GLP-1s alone. Abbott presented the findings at the Advanced Technologies & Treatments for Diabetes […]
Tandem Diabetes Care prices $275M offering
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it priced an offering of convertible senior notes worth $275 million. The San Diego-based automated insulin delivery technology developer plans to sell the notes, due 2029, to qualified institutional buyers. It upsized the offering from the previously announced $250 million aggregate principal amount. The company also offered initial […]
FDA clears first over-the-counter CGM from Dexcom
Dexcom (Nasdaq:DXCM) announced today that the FDA cleared its Stelo glucose biosensor that does not require a prescription. This marks the first FDA clearance for a continuous glucose monitoring (CGM) technology for over-the-counter use. In January, Dexcom first announced that it submitted the new Stelo sensor to the FDA for review at the end of last […]
Dexcom announces direct-to-watch feature for G7 CGM, strong automated insulin delivery outcomes
Dexcom (Nasdaq:DXCM) announced today that it introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year. This means G7 soon becomes the only CGM system that can connect directly to Apple […]
Know Labs to raise up to $12M for non-invasive CGM tech
Know Labs (NYSE:KNW) announced that it entered into a funding agreement for an investment worth up to $12 million. The Seattle-based company executed a $4 million close as part of this investment with Lind Global Fund II. The Lind Partners, a New York-based institutional fund manager, manages Lind Global Fund II. Funding helps Know Labs […]
FDA submission for 365-day CGM from Senseonics is ‘imminent’
Senseonics (NYSE:SENS) shares dipped after hours on fourth-quarter results that came in ahead of the consensus forecast. The company also reported an “imminent” submission of its latest, longest-lasting continuous glucose monitoring (CGM) technology. Shares of SENS fell 3.5% to 69¢ apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of […]
Report: Insulet trumps Medtrum again in French patent spat
JUVE-Patent reports that the Judicial Court of Paris again ruled in favor of Insulet (Nasdaq:PODD) in its patent battle with Medtrum. According to the report, the court sided with Insulet in a case regarding the company’s patent (EP 1 874 390). The ruling finds that Medtrum’s A6 and A7+ TouchCare insulin pump devices infringe the valid […]
These diabetes devices are set to launch in 2024
The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few […]
Know Labs unveils wearable, non-invasive CGM set for FDA submission
Know Labs (NYSE:KNW) today unveiled KnowU, its wearable, non-invasive continuous glucose monitor (CGM) system. Seattle-based Know Labs first announced its initial prototype last June. It says KnowU is the result of an accelerated development process over the past eight months. The system incorporates the sensor developed by the company that it plans to submit for […]